首页> 外国专利> ENHANCED IMMUNOTHERAPY OF CANCER USING TARGETED TRANSCRIPTIONAL MODULATORS

ENHANCED IMMUNOTHERAPY OF CANCER USING TARGETED TRANSCRIPTIONAL MODULATORS

机译：使用靶向转录调节剂增强癌症的免疫治疗

页面导航

摘要
著录项
相似文献

摘要

The present invention relates to a combination of a signal transducer and activator of transcription 3 (STAT3) activity inhibitor; and an immune checkpoint inhibitor for use in treating or preventing the hyperproliferative disorder in a subject. Preferably, the STA3 activity inhibitor is pyrimethamine or atovaquone, and the immune checkpoint inhibitor is an anti-PD1 antibody. Preferably, the hyperproliferative disorder is a glioma or a glioblastoma.

机译：本发明涉及信号转导子和转录激活因子3（STAT3）活性抑制剂的组合。用于治疗或预防受试者过度增殖性疾病的免疫检查点抑制剂。优选地，STA3活性抑制剂是乙胺嘧啶或阿托伐醌，而免疫检查点抑制剂是抗PD1抗体。优选地，过度增殖性疾病是神经胶质瘤或成胶质细胞瘤。

著录项

公开/公告号WO2019023525A1

专利类型
公开/公告日2019-01-31

原文格式PDF
申请/专利权人 DANA-FARBER CANCER INSTITUTE INC.;
展开▼

申请/专利号WO2018US43997
发明设计人 FRANK DAVID;YE DARWIN;
展开▼

申请日2018-07-27
分类号A61K31/122;A61K31/505;A61K45/06;A61P35;A61P35/02;C07K16/28;
国家 WO
入库时间 2022-08-21 11:56:59

相似文献

专利
外文文献
中文文献